| Detected | Trial | Change |
|---|---|---|
| 2026-05-28 | NCT07190222 Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult… |
Trial sites expanded: 194 -> 206 locations |
| 2026-05-28 | NCT07190209 Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult… |
Trial sites expanded: 183 -> 196 locations |
| 2026-05-28 | NCT06676319 Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma |
Trial sites reduced: 236 -> 230 locations |
| 2026-05-21 | NCT06914908 Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic… |
overall status: "Recruiting" → "Enrolling By Invitation" |
| 2026-05-20 | NCT06609239 Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants… |
overall status: "Recruiting" → "Enrolling By Invitation" |
| 2026-05-20 | NCT06609239 Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants… |
Primary endpoint(s) modified |
| 2026-05-16 | NCT06609239 Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants… |
Trial sites expanded: 118 -> 122 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult… | Chronic Obstructive Pulmonary Disease | Recruiting |
| NCT07190222 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult… | Chronic Obstructive Pulmonary Disease | Recruiting |
| Phase 2 | |||
| NCT06676319 | Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Asthma | Recruiting |
| NCT06609239 | Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants… | Asthma | Enrolling by Invitation |
| NCT06914908 | Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic… | Chronic Rhinosinusitis With Nasal Polyps | Enrolling by Invitation |